Successes and setbacks of early investigational drugs for melanoma

Emerging and investigational drugs for premature ejaculation

Over the past 20-30 years, the premature ejaculation (PE) treatment paradigm, previously limited to behavioural psychotherapy, has expanded to include drug treatment. Pharmacotherapy for PE predominantly targets the multiple neurotransmitters and receptors involved in the control of ejaculation which include serotonin, dopamine, oxytocin, norepinephrine, gamma amino-butyric acid (GABA) and nitr...

Investigational drugs and the law.

The regulation of investigational drugs.

THE search for effective drugs to combat the acquired immunodeficiency syndrome (AIDS) has focused renewed attention on the process by which the U.S. Food and Drug Administration(FDA) regulates the development and availability of new therapeutic agents. The federal government’s ability to strike the difficult balance between ensuring the safety of patients and accelerating the availability of n...

New and investigational antiretroviral drugs for HIV infection: mechanisms of action and early research findings.

Numerous investigational antiretroviral agents are in clinical development. Among them are festinavir (BMS986001), a thymidine analogue similar to stavudine with reduced potential for toxicity; GS-7340, a prodrug of tenofovir that achieves greater intracellular concentrations; MK-1439, a nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) that retains activity against common NNRTI-as...

New investigational drugs for androgenetic alopecia.

INTRODUCTION Androgenetic alopecia (AGA) is the most common form of hair loss, however current treatment options are limited and moderately effective. In the past few years, there has been an increased interest in deciphering the molecular mechanisms responsible for this disorder, which has opened the possibility of novel treatments that promise to not only stimulate hair growth, but also to in...